Literature DB >> 20605708

Contemporary post surgical management of differentiated thyroid carcinoma.

H Tala1, R M Tuttle.   

Abstract

Risk assessment is the cornerstone of contemporary management of thyroid cancer. Following thyroid surgery, an initial risk assessment of recurrence and disease-specific mortality is made using important intra-operative findings, histologic characteristics of the tumor, molecular profile of the tumor, post-operative serum thyroglobulin and any available cross-sectional imaging studies. This initial risk assessment is used to guide recommendations regarding the need for remnant ablation, external beam irradiation, systemic therapy, degree of TSH suppression, and follow-up disease detection strategy over the first 2 years after initial therapy. While this initial risk stratification provides valuable information, it is a static representation of the patient in the first few weeks post-operatively that does not change over time. Depending on how the patient responds to our initial therapies, the risk of recurrence and death may change significantly during follow-up. In order to account for differences in response to therapy in individual patients and to incorporate the impact of treatment on our initial risk estimates, we recommend a re-stratification of risk at the 2-year point of follow-up. This re-stratification provides an updated risk estimate that can be used to guide ongoing management recommendations including the frequency and intensity of follow-up, degree of ongoing TSH suppression, and need for additional therapies. Ongoing management recommendations must be tailored to realistic, evolving risk estimates that are actively updated during follow-up. By individualizing therapy on the basis of initial and ongoing risk assessments, we can maximize the beneficial effects of aggressive therapy in patients with thyroid cancer who are likely to benefit from it, while minimizing potential complications and side effects in low-risk patients destined to have a full healthy and productive life after minimal therapeutic intervention. Copyright (c) 2010 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20605708     DOI: 10.1016/j.clon.2010.04.005

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN: 0936-6555            Impact factor:   4.126


  15 in total

1.  Predictors of incomplete response to therapy among Filipino patients with papillary thyroid cancer in a tertiary hospital.

Authors:  E S Mendoza; A A Lopez; V A U Valdez; E C Cunanan; B J Matawaran; S A Kho; M H Sero-Gomez
Journal:  J Endocrinol Invest       Date:  2015-06-03       Impact factor: 4.256

2.  Quality of life-in patients with differentiated thyroid cancer at the general endocrinology clinics of the University Hospital of Puerto Rico.

Authors:  Mónica A Vega-Vázquez; Loida Gonzalez-Rodriguez; Eduardo J Santiago-Rodríguez; Anette Garcés-Domínguez; Lee-Ming Shum; Maribel Tírado-Gómez; Margarita Ramírez-Vick
Journal:  Bol Asoc Med P R       Date:  2015 Jan-Mar

3.  Optimal management of a biochemical incomplete response to therapy in differentiated thyroid cancer: aggressive treatment or cautious observation?

Authors:  R Michael Tuttle
Journal:  Endocrine       Date:  2014-03-11       Impact factor: 3.633

Review 4.  Post-treatment surveillance of thyroid cancer.

Authors:  L Y Wang; I Ganly
Journal:  Eur J Surg Oncol       Date:  2017-07-19       Impact factor: 4.424

5.  Recombinant human thyroid-stimulating hormone-aided remnant ablation achieves a response to treatment comparable to that with thyroid hormone withdrawal in patients with clinically relevant lymph node metastases.

Authors:  Fabián Pitoia; Erika Abelleira; Graciela Cross
Journal:  Eur Thyroid J       Date:  2014-12-06

6.  RAI thyroid bed uptake after total thyroidectomy: A novel SPECT-CT anatomic classification system.

Authors:  Rebecca Zeuren; Agnese Biagini; Ravinder K Grewal; Gregory W Randolph; Dipti Kamani; Mona M Sabra; Ashok R Shaha; R Michael Tuttle
Journal:  Laryngoscope       Date:  2015-04-17       Impact factor: 3.325

7.  Five-year longitudinal evaluation of quality of life in a cohort of patients with differentiated thyroid carcinoma.

Authors:  Massimo Giusti; Giulia Melle; Monica Fenocchio; Lorenzo Mortara; Francesca Cecoli; Valeria Caorsi; Diego Ferone; Francesco Minuto; Elda Rasore
Journal:  J Zhejiang Univ Sci B       Date:  2011-03       Impact factor: 3.066

8.  Biochemical persistence in thyroid cancer: is there anything to worry about?

Authors:  Fabián Pitoia; Pitoia Fabián; Erika Abelleira; Abelleira Erika; Hernán Tala; Tala Hernán; Fernanda Bueno; Bueno Fernanda; Carolina Urciuoli; Urciuoli Carolina; Graciela Cross; Cross Graciela
Journal:  Endocrine       Date:  2013-11-28       Impact factor: 3.633

9.  Controversies in the management and followup of differentiated thyroid cancer: beyond the guidelines.

Authors:  Hala Ahmadieh; Sami T Azar
Journal:  J Thyroid Res       Date:  2012-12-30

10.  New molecular targeted therapy and redifferentiation therapy for radioiodine-refractory advanced papillary thyroid carcinoma: literature review.

Authors:  Kai-Pun Wong; Brian Hung-Hin Lang
Journal:  J Thyroid Res       Date:  2012-12-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.